Literature DB >> 32064089

Telmisartan-induced sprue-like enteropathy: a case report.

Natalia Alzueta1, Amaya Echeverría1, Lorea Sanz1, Carmen Fontela1, Teresa Acín1, Lidia Montenegro1, Javier Garjón1.   

Abstract

A possible case of sprue-like enteropathy (SLE) induced by the use of telmisartan is reported. Telmisartan is an angiotensin-receptor II blocker (type 1) used for the treatment of hypertension. Several cases of SLE associated with olmesartan and other drugs of the same group have been reported. In all cases, SLE resolved following therapy withdrawal. We describe the case of an 80-year-old woman who presented with diarrhoea and abdominal pain. In the past 5 years she had been treated with telmisartan 40 mg once a day for hypertension, so we hypothesised that symptoms might be caused by telmisartan. After treatment discontinuation, diarrhoea disappeared. Three causality algorithms were applied and revealed a possible or likely causal relationship. At present, the patient remains asymptomatic. There is a causal relationship between the use of telmisartan and SLE. This association should be taken into account by physicians when prescribing and reviewing drug therapies. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  adverse event; angiotensin-receptor Ii blocker; diarrhea; sprue-like enteropathy; telmisartan

Year:  2018        PMID: 32064089      PMCID: PMC6992972          DOI: 10.1136/ejhpharm-2018-001669

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  11 in total

1.  Severe spruelike enteropathy associated with olmesartan.

Authors:  Alberto Rubio-Tapia; Margot L Herman; Jonas F Ludvigsson; Darlene G Kelly; Thomas F Mangan; Tsung-Teh Wu; Joseph A Murray
Journal:  Mayo Clin Proc       Date:  2012-06-22       Impact factor: 7.616

2.  Letter: telmisartan associated enteropathy - is there any class effect? Authors' reply.

Authors:  G Cammarota; G Ianiro; S Bibbò; A Gasbarrini
Journal:  Aliment Pharmacol Ther       Date:  2014-09       Impact factor: 8.171

3.  Letter: telmisartan-associated enteropathy - is there any class effect?

Authors:  J Cyrany; T Vasatko; J Machac; M Nova; J Szanyi; M Kopacova
Journal:  Aliment Pharmacol Ther       Date:  2014-09       Impact factor: 8.171

Review 4.  Systematic review: Sprue-like enteropathy associated with olmesartan.

Authors:  G Ianiro; S Bibbò; M Montalto; R Ricci; A Gasbarrini; G Cammarota
Journal:  Aliment Pharmacol Ther       Date:  2014-05-07       Impact factor: 8.171

5.  Toward the operational identification of adverse drug reactions.

Authors:  F E Karch; L Lasagna
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

6.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Olmesartan-associated enteropathy: results of a national survey.

Authors:  L Marthey; G Cadiot; P Seksik; P Pouderoux; J Lacroute; F Skinazi; B Mesnard; J A Chayvialle; G Savoye; A Druez; D Parlier; V Abitbol; M Gompel; M Eoche; E Poncin; R Bobichon; P Colardelle; P Wils; H Salloum; S Peschard; F Zerbib; B Méresse; N Cerf-Bensussan; G Malamut; F Carbonnel
Journal:  Aliment Pharmacol Ther       Date:  2014-09-09       Impact factor: 8.171

8.  Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug.

Authors:  Jennifer A Nielsen; Anita Steephen; Matthew Lewin
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

9.  A Case of Moderate Sprue-Like Enteropathy Associated With Telmisartan.

Authors:  Aurelio Negro; Loredana De Marco; Valentina Cesario; Rosaria Santi; Maria Chiara Boni; Magda Zanelli
Journal:  J Clin Med Res       Date:  2017-11-06

10.  Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers.

Authors:  Harshal Surendra Mandavdhare; Vishal Sharma; Kaushal K Prasad; Amit Kumar; Manish Rathi; Surinder S Rana
Journal:  Intest Res       Date:  2017-06-12
View more
  1 in total

1.  Serum Untargeted Metabolism Reveals the Mechanism of L. plantarum ZDY2013 in Alleviating Kidney Injury Induced by High-Salt Diet.

Authors:  Cuixiang Wan; Shufang Chen; Kui Zhao; Zhongyue Ren; Lingling Peng; Huiling Xia; Hua Wei; Bo Yu
Journal:  Nutrients       Date:  2021-11-01       Impact factor: 5.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.